Phase 1b dose expansion and translational analyses of olaparib in combination with the oral AKT inhibitor capivasertib in recurrent endometrial, triple negative breast, and ovarian, primary peritoneal, or fallopian tube cancerShannon N. Westin, Gordon B. Mills, Allison Creason et al.|medRxiv|2021Cited by 11